CD274 and non-small cell lung carcinoma: Based on the findings in KEYNOTE-001, KEYNOTE-024 further investigated the efficacy of first-line pembrolizumab monotherapy in advanced NSCLC patients with PD-L1 TPS ≥50% and compared it with chemotherapy (20).